Credit: MART PRODUCTION from Pexels A University of Alberta study shows that PET/CT imaging using a new tracing agent is more accurate at determining the extent of prostate cancer than the current standard MRI for intermediate and high-risk cases. In research published this week in the journal JAMA Oncology, the researchers report that the new test correctly predicted the location and margin of tumors in 45% of cases—nearly twice as often as the rate of 28% for MRI. “This is very important because we make a lot of treatment decisions Read More